Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q9UPY3: Variant p.Asp1709Tyr

Endoribonuclease Dicer
Gene: DICER1
Feedback?
Variant information Variant position: help 1709 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Aspartate (D) to Tyrosine (Y) at position 1709 (D1709Y, p.Asp1709Tyr). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and acidic (D) to large size and aromatic (Y) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In GLOW; somatic mutation. Any additional useful information about the variant.


Sequence information Variant position: help 1709 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 1922 The length of the canonical sequence.
Location on the sequence: help HASYHYNTITDCYQRLEFLG D AILDYLITKHLYEDPRQHSP The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         HASYHYNTITDCYQRLEFLGDAILDYLITKHLYEDPRQHSP

Mouse                         HASYHYNTITDCYQRLEFLGDAILDYLITKHLYEDPRQHSP

Bovine                        HASYHYNTITDCYQRLEFLGDAILDYLITKHLYEDPRQHSP

Chicken                       HASYHYNTITDCYQRLEFLGDAILDYLITKHLYEDPRQHSP

Xenopus tropicalis            HASYHYNTITDCYQRLEFLGDAILDYLITKHLYEDPRQHSP

Zebrafish                     HASYHYNTITDCYQRLEFLGDAILDYLITKHLYEDPRQHSP
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 1922 Endoribonuclease Dicer
Domain 1666 – 1824 RNase III 2
Binding site 1705 – 1705
Mutagenesis 1702 – 1702 Q -> A. No effect on activity.
Mutagenesis 1709 – 1709 D -> A. Decreased activity. Loss of activity; when associated with D-1320.
Mutagenesis 1729 – 1729 P -> E. No effect on activity.
Helix 1702 – 1722



Literature citations
Expanding the phenotype of mutations in DICER1: mosaic missense mutations in the RNase IIIb domain of DICER1 cause GLOW syndrome.
Klein S.; Lee H.; Ghahremani S.; Kempert P.; Ischander M.; Teitell M.A.; Nelson S.F.; Martinez-Agosto J.A.;
J. Med. Genet. 51:294-302(2014)
Cited for: VARIANTS LEU-435 AND GLY-1898; VARIANTS GLOW TYR-1709 AND VAL-1713; INVOLVEMENT IN GLOW;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.